These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 14532137)

  • 1. Advances in targeted therapies V: Proceedings of the 5th International Symposium. St Martin, French West Indies. 11-14 April 2003.
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2():ii1-96. PubMed ID: 14532137
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and efficacy of the biologic response modifiers.
    Markenson J
    Am J Orthop (Belle Mead NJ); 2007 Mar; 36(3 Suppl):15-9. PubMed ID: 17491583
    [No Abstract]   [Full Text] [Related]  

  • 3. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Dougados M; Emery P; Gibofsky A; Kavanaugh AF; Keystone EC; Klareskog L; Russell AS; van de Putte LB; Weisman MH
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii2-9. PubMed ID: 14532138
    [No Abstract]   [Full Text] [Related]  

  • 4. [Biopharmaceuticals in the treatment of rheumatoid arthritis].
    Baslund B; Bendtzen K
    Ugeskr Laeger; 2008 Jun; 170(24):2108-10. PubMed ID: 18572481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proposed guidelines for the clinical evaluation of interleukin-1 inhibitors in the treatment of rheumatoid arthritis.
    Dougados M
    Eur Cytokine Netw; 1990; 1(4):235-7. PubMed ID: 2151768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade.
    Redlich K; Schett G; Steiner G; Hayer S; Wagner EF; Smolen JS
    Arthritis Rheum; 2003 Dec; 48(12):3308-19. PubMed ID: 14673982
    [No Abstract]   [Full Text] [Related]  

  • 7. Rheumatoid arthritis.
    Ramsburg KL
    Am J Nurs; 2000 Nov; 100(11):40-3. PubMed ID: 11103634
    [No Abstract]   [Full Text] [Related]  

  • 8. [Off-label use of biological therapies in systemic diseases].
    Hachulla E
    Rev Med Interne; 2010 Dec; 31 Suppl 3():S307-14. PubMed ID: 21036424
    [No Abstract]   [Full Text] [Related]  

  • 9. Advances in Targeted Therapies VI. Proceedings of the 6th International Symposium. Venice, Italy, 28 April-2 May 2004.
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2():ii1-101. PubMed ID: 15479863
    [No Abstract]   [Full Text] [Related]  

  • 10. [Role of TNF-alpha and cytokines in the physiopathology of rheumatoid arthritis. Therapeutic perspectives].
    Meyer O
    Bull Acad Natl Med; 2003; 187(5):935-54; discussion 954-5. PubMed ID: 14979058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rheumatoid arthritis: anticytokine therapies on the horizon.
    Koopman WJ; Moreland LW
    Ann Intern Med; 1998 Feb; 128(3):231-3. PubMed ID: 9454532
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of rheumatoid arthritis with cytokine antagonists].
    Manger B
    Z Arztl Fortbild Qualitatssich; 1999 Mar; 93(2):101-4. PubMed ID: 10355058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Rheumatoid arthritis. Biologic treatments].
    Rodríguez-Valverde V
    Rev Clin Esp; 2000 May; 200 Monog 1():107-13. PubMed ID: 10901035
    [No Abstract]   [Full Text] [Related]  

  • 14. [Redefining treatment of rheumatic arthritis with anti-cytokines].
    Gabay C; So A
    Rev Med Suisse; 2007 Mar; 3(103):715-7. PubMed ID: 17458148
    [No Abstract]   [Full Text] [Related]  

  • 15. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
    Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
    Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New drugs and treatment strategies for rheumatoid arthritis].
    Fantini F
    Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of intra-articular anti-tumor necrosis factor α agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare.
    Carubbi F; Zugaro L; Cipriani P; Conchiglia A; Gregori L; Danniballe C; Letizia Pistoia M; Liakouli V; Ruscitti P; Ciccia F; Triolo G; Masciocchi C; Giacomelli R
    Int J Immunopathol Pharmacol; 2016 Jun; 29(2):252-66. PubMed ID: 26684633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of biological agents in immune-mediated inflammatory diseases.
    Efthimiou P; Markenson JA
    South Med J; 2005 Feb; 98(2):192-204. PubMed ID: 15759950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current conception of rheumatoid polyarthritis treatment: towards a therapeutic revolution?].
    Sany J
    Bull Acad Natl Med; 2003; 187(5):957-73; discussion 973-6. PubMed ID: 14979059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rheumatoid arthritis: current status of therapy].
    El Bahri DM; Meddeb N; Sellami S
    Tunis Med; 2007 Jan; 85(1):1-8. PubMed ID: 17424701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.